The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | How important is NGS for biomarker testing in NSCLC?
Joshua Sabari, MD, New York University Langone Health, New York, NY, emphasizes the importance of next-generation sequencing (NGS) in identifying biomarkers that drive therapeutic options for patients with non-small cell lung cancer (NSCLC). Testing for biomarkers such as HER2 exon 20, EGFR, and KRAS is crucial in allowing patients to benefit from targeted therapies. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think ASCO 2025 has been an amazing experience. The key for me still is NGS, NGS, NGS. If you don’t test, you can’t identify biomarkers that are going to help drive therapeutic options for patients. From HER2 exon 20, as we discussed, to EGFR to KRAS, we are developing more and more targeted therapeutic options for our patients. So if we don’t test our patients and we don’t identify those biomarkers, we can’t allow patients to benefit from our therapeutics...
I think ASCO 2025 has been an amazing experience. The key for me still is NGS, NGS, NGS. If you don’t test, you can’t identify biomarkers that are going to help drive therapeutic options for patients. From HER2 exon 20, as we discussed, to EGFR to KRAS, we are developing more and more targeted therapeutic options for our patients. So if we don’t test our patients and we don’t identify those biomarkers, we can’t allow patients to benefit from our therapeutics.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting or Advisory Role – Abbvie; AstraZeneca; Genentech/Roche; Janssen; Janssen (Inst); Loxo/Lilly; Loxo/Lilly (Inst); Medscape; Mirati Therapeutics; Mirati Therapeutics (Inst); Pfizer; Regeneron; Regeneron (Inst); Sanofi; Takeda
